Marathon Pharmaceuticals LLC
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Marathon Pharmaceuticals LLC
Finance Watch: Biotech Venture Capital Had Its Biggest Quarter Ever
Private Company Edition: VC mega-rounds boosted the Q1 2021 total. Also, new funds from Versant, The Column Group and Rapha Capital keep cash flowing into biopharma; up to $525m is invested in Exscientia; and Arch Oncology and Boundless Bio raised $105m each, while Forge brought in $120m.
Tech Transfer Roundup: MD Anderson Tackles Cancer In Alliances With UroGen, Xencor, Obsidian
In tandem with buying the rest of Kleo, Tonix licenses molecular degradation technology from Yale. Neurogene, University of Dundee partner on cell therapies for neurological disorders.
PTC Eyes Transition From Capital-Raising To Money-Making Company
With $1.1bn in cash plus revenue from its existing commercial products and royalties from Roche’s sales of newly approved Evrysdi to invest in R&D, PTC Therapeutics may achieve profitability in 2023.
At Paragon, Jeffrey Aronin Has Launched His Next Act – Or Eight Of Them
Jeffrey Aronin, who presided over Marathon Pharmaceuticals during a drug-pricing kerfuffle that drew congressional scrutiny, has built a portfolio of new drug companies at Paragon Biosciences.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals